Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Republican Wisconsin Sen. Ron Johnson is sounding the alarm about the deficit impact of President Donald Trump’s “big, ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Sonya Johnson, 41, started taking drugs at age 11, when a man who was sexually abusing her gave them to her behind her ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

Six years after her son was killed by a Seattle police officer involved in multiple deadly encounters, a federal judge ...

Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as the ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

Mental health has not always been talked about within communities of color, but that is starting to shift because of people ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

There are 22 former Detroit Lions in the Pro Football Hall of Famers. But who are the four greatest among them? We took a ...